Denominazione

Genomic analysis of myeloid neoplasms and development of molecular diagnostic tools and innovative therapies

Attività di ricerca

Myeloid neoplasms include myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

MPN are characterized by clonal proliferation of hematopoietic stem cells and overproduction of mature blood cells: these disorders include polycythemia vera, essential thrombocythemia and primary myelofibrosis, which have a variable propensity to thrombosis and leukemic transformation. In 2005, by studying loss of heterozygosity (LOH) of chromosomes 9p we found that most patients with MPN carry the JAK2 (V617F) mutation. This somatic gain-of-function mutation provides a proliferative advantage, leading to clonal proliferation of hematopoietic cells. We are currently studying familial MPN with the aim of defining their genetic predisposition to the acquisition of JAK2 (V617F). Using high resolution SNP microarrays, we are also analyzing the genomic aberrations that underlie leukemic transformation. Finally, we are participating in clinical trials on the use of JAK2 inhibitors for treatment of patients with MPN.

MDS are characterized by clonal proliferation of hematopoietic stem cells, which partly retain their capacity to differentiate and maturate, but do so in an inefficient manner. Clones of hematopoietic cells carrying non-random cytogenetic abnormalities are typically found in these patients. With time there is a progressive impairment in the capacity of hematopoietic cells to differentiate, and a significant portion of patients evolve into AML. We have developed a prognostic model that predicts survival and leukemia progression at any time during follow-up. In the next years, using novel sequencing technologies for cancer genomics, we plan to characterize the genomic architecture of MDS. Basically we will study genomic DNA from circulating granulocytes (myelodysplastic genome) and from circulating T lymphocytes (normal control genome). We will perform mutation analysis of candidate genes, search for chromosomal regions of LOH and copy number variation (CNV), point mutation screen of selected regions of the genome, and whole exome sequencing in representative patients.

Parole chiave

Obbligate
  • LS6_1 - Biological basis of non-communicable diseases, except for neural/psychiatric, immunity-related and metabolism-related disorders.
  • LS6_2 - Diagnostics
  • LS6_3 - Therapies: drug therapies, gene therapy, surgery

 

Libere
  • Myeloid neoplasm
  • Myeloproliferative neoplasm
  • Myelodysplastic syndrome
  • Acute myeloid leukemia
  • Targeted therapy

 

Coordinatore

Mario Cazzola
Professore Ordinario
Dipartimento Di Medicina Molecolare
Clinica Ematologica, Fondazione Irccs Policlinico San Matteo - Pavia
Tel. +39-0382-503595 - Mob.
E-mail: mario.cazzola@unipv.it

Profilo del coordinatore

Curriculum Vitae

Mario Cazzola is a full Professor of Hematology at the University of Pavia Medical School.

In the early 80's he collaborated with Clem Finch at the University of Washington School of Medicine, Seattle, on studies on the pathophysiology of anemia in man. From 1998 to 2006, he coordinated a national project aimed at defining the molecular basis of inherited disorders of iron metabolism. These investigations led to the identification of novel genes and proteins of iron metabolism, and the definition of translational pathophysiology as a novel molecular mechanism of human disease (Blood. 2000;95:3280-8).

Current research interests mainly concern myelodysplastic syndromes and myeloproliferative neoplasms. The studies on myelodysplastic syndromes are conducted in collaboration with Jacqueline Boultwood, Molecular Haematology Unit, Oxford, Eva Hellstrom-Lindberg, Karolinska University Hospital, Stockholm, and Ulrich Germing, Heinrich-Heine-University, Duesseldorf. These investigations led to the definition of specific gene expression profiles in myelodysplastic syndromes (Blood. 2006;108:337-45 - Leukemia. 2010;24:756-64), the identification of the molecular basis of refractory anemia with ring sideroblasts associated with marked thrombocytosis (Blood. 2009;114:3538-45), and the development of WPSS [J Clin Oncol. 2007;25:3503-10) for risk assessment in myelodysplastic syndromes.

The studies on myeloproliferative neoplasms are performed in collaboration with Radek Skoda, University Hospital Basel, Basel, and Robert Kralovics, Center for Molecular Medicine, Vienna. These investigations led to the identification of the unique gain-of-function mutation of JAK2 in myeloproliferative neoplasms (N Engl J Med. 2005;35217:1779-90), the recognition of familial disorders (J Clin Oncol. 2007;25:5630-5) and the definition of novel prognostic factors (Leukemia. 2010;24:1574-9).

Current studies on myeloid neoplasms are funded by AIRC Special Program Molecular Clinical Oncology 5 per mille.

 

Pubblicazioni più significative degli ultimi 5 anni (max 5)
DELLA PORTA, MATTEO GIOVANNI; MALCOVATI, LUCA; Boveri E; Travaglino E; Pietra D; Pascutto C; PASSAMONTI, FRANCESCO; INVERNIZZI, ROSANGELA; CASTELLO, ALESSANDRO; MAGRINI, UMBERTO; LAZZARINO, MARIO; CAZZOLA, MARIO
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome
Rivista: JOURNAL OF CLINICAL ONCOLOGY - Volume: 27 - Pagine: 754-762 - Num. pagine: 9 - Anno: 2009
(1 Contributo su Rivista)
MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Pietra D; Boveri E; Pellagatti A; Gallì A; Travaglino E; Brisci A; RUMI, ELISA; PASSAMONTI, FRANCESCO; INVERNIZZI, ROSANGELA; Cremonesi L; Boultwood J; Wainscoat JS; Hellström Lindberg E; CAZZOLA, MARIO
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Rivista: BLOOD - Volume: 114 - Pagine: 3538-3545 - Num. pagine: 8 - Anno: 2009
(1 Contributo su Rivista)
Pietra D; Li S; Brisci A; PASSAMONTI, FRANCESCO; RUMI, ELISA; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; CAZZOLA, MARIO
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders
Rivista: BLOOD - Volume: 111 - Pagine: 1686-1689 - Num. pagine: 4 - Anno: 2008
(1 Contributo su Rivista)
PASSAMONTI, FRANCESCO; RUMI, ELISA; Pietra D; DELLA PORTA, MATTEO GIOVANNI; Boveri E; Pascutto C; Vanelli L; ARCAINI, LUCA; Burcheri S; MALCOVATI, LUCA; LAZZARINO, MARIO; CAZZOLA, MARIO
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
Rivista: BLOOD - Volume: 107 - Pagine: 3676-3682 - Num. pagine: 7 - Anno: 2006
(1 Contributo su Rivista)
Kralovics R; PASSAMONTI, FRANCESCO; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; CAZZOLA, MARIO; Skoda RC
A gain-of-function mutation of JAK2 in myeloproliferative disorders
Rivista: NEW ENGLAND JOURNAL OF MEDICINE - Volume: 352 - Pagine: 1779-1790 - Anno: 2005
(1 Contributo su Rivista)

 

Indici
  • ISI (dal 1990):
    • Numero di citazioni complessivo: >6000
    • H index: 41
  • SCOPUS (dal 1996):
    • Numero di citazioni complessivo: >6000
    • H index: 41
  • GOOGLE SCHOLAR:
    • H index: 51

     

Membri dell'unità di ricerca

Afferenti all'Università di Pavia
1 Della Porta Matteo Giovanni Ricercatore H Index ISI: 19
Dip.Med.Interna - Sez.Endocrinologia E Oncologia Medica
2 Malcovati Luca Ricercatore H Index ISI: 17
Dipartimento Di Medicina Molecolare
3 Passamonti Francesco Ricercatore H Index ISI: 20
Dipartimento Di Medicina Molecolare
4 Rumi Elisa Ricercatore a tempo determinato H Index ISI: 10
Dipartimento Di Medicina Molecolare

 

Afferenti ad altri enti/istituzioni
1 Elena Chiara Hematologist
Fondazione IRCCS Policlinico San Matteo Italia
2 Gallì Anna Biologist
Fondazione IRCCS Policlinico San Matteo Italia
3 Pietra Daniela Molecular Biologist H Index ISI: 11
Fondazione IRCCS Policlinico San Matteo Italia

 

Collaborazioni strategiche

1 Boultwood Jacqueline
Molecular Haematology Unit, John Radcliffe Hospital, Oxford Regno Unito
2 Campbell Peter
Wellcome Trust Sanger Institute, Cambridge Regno Unito
3 Germing Ulrich
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf Germania
4 Hellström-Lindberg Eva
Experimental Hematology, Karolinska Institutet, Stockholm Svezia
5 Kralovics Robert
Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna Austria
6 Skoda Radek
Experimental Hematology, University Hospital, Basel Svizzera

 

Finanziamenti - Principali progetti finanziati negli ultimi 5 anni

Fonte finanziamento/
tipologia progetto
Nome progetto Inizio progetto Durata progetto
Fondazione Cariplo Genomic analysis of hematopoietic cells in Philadelphia-negative chronic myeloproliferative disorders 2005 36 M
Associazione Italiana per la Ricerca sul Cancro Genomic analysis of hematopoietic cells in myelodysplastic syndromes and myeloproliferative disorders 2006 36 M
MIUR PRIN Genomic and functional analysis of hematopoietic cells in chronic myeloproliferative disorders 2007 24 M
Fondazione Cariplo Molecular basis of Philadelphia-negative myeloproliferative disorders 2008 36 M
Associazione Italiana per la Ricerca sul Cancro Molecular basis, prognosis and treatment of myelodysplastic syndromes and myeloproliferative neoplasms 2009 36 M
Regione Lombardia Molecular and cellular basis of myelodysplastic syndromes and myeloproliferative neoplasms: development of innovative diagnostic methods and prognostic models 2010 24 M
MIUR PRIN Molecular basis of Philadelphia-negative myeloproliferative neoplasms and development of innovative therapies 2010 24 M
Associazione Italiana per la Ricerca sul Cancro An integrated platform for molecular studies and clinical trials in chronic myeloproliferative neoplasms 2010 36 M

Prodotti dell'unità di ricerca

Altre pubblicazioni (max 30)
Boveri E; ARCAINI, LUCA; Merli M; Passamonti F; Rizzi S; Vanelli L; RUMI, ELISA; Rattotti S; Lucioni M; Picone C; Castello A; Pascutto C; Lazzarino M; MAGRINI, UMBERTO; Paulli M.
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients
Rivista: ANNALS OF ONCOLOGY - Volume: 20(1):129-36 - Pagine: 129-136 - Num. pagine: 8 - Anno: 2009
(1 Contributo su Rivista)
Cervantes F; Dupriez B; Pereira A; PASSAMONTI, FRANCESCO; Reilly JT; Morra E; Vannucchi AM; Mesa RA; Demory JL; Barosi G; RUMI, ELISA; Tefferi A.
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Rivista: BLOOD - Volume: 113 - Pagine: 2895-2901 - Num. pagine: 7 - Anno: 2009
(1 Contributo su Rivista)
Olcaydu D; Skoda RC; Looser R; Li S; CAZZOLA, MARIO; Pietra D; PASSAMONTI, FRANCESCO; Lippert E; Carillo S; Girodon F; Vannucchi A; Reading NS; Prchal JT; Ay C; Pabinger I; Gisslinger H; Kralovics R.
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.
Rivista: LEUKEMIA - Volume: 23 - Pagine: 1924-1926 - Num. pagine: 3 - Anno: 2009
(1 Contributo su Rivista)
Pellagatti A; Marafioti T; Paterson JC; MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Jädersten M; Pushkaran B; George TI; Arber DA; Killick S; Giagounidis A; Hellström Lindberg E; CAZZOLA, MARIO; Wainscoat JS; Boultwood J.
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
Rivista: BRITISH JOURNAL OF HAEMATOLOGY - Volume: 146 - Pagine: 86-90 - Num. pagine: 5 - Anno: 2009
(1 Contributo su Rivista)
Alessandrino EP; DELLA PORTA, MATTEO GIOVANNI; Bacigalupo A; Van Lint MT; Falda M; Onida F; Bernardi M; Iori AP; Rambaldi A; Cerretti R; Marenco R; Pioltelli P; MALCOVATI, LUCA; PASCUTTO, CRISTIANA; Oneto R; Fanin R; Bosi A.
WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Rivista: BLOOD - Volume: 112 - Pagine: 895-902 - Num. pagine: 8 - Anno: 2008
(1 Contributo su Rivista)
Barosi G; Mesa RA; Thiele J; Cervantes F; Campbell PJ; Verstovsek S; Dupriez B; Levine RL; PASSAMONTI, FRANCESCO; Gotlib J; Reilly JT; Vannucchi AM; Hanson CA; Solberg LA; Orazi A; Tefferi A.
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
Rivista: LEUKEMIA - Volume: 22 - Pagine: 437-438 - Anno: 2008
(1 Contributo su Rivista)
Boultwood J; Pellagatti A; Nikpour M; Pushkaran B; Fidler C; Cattan H; Littlewood TJ; MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Jädersten M; Killick S; Giagounidis A; Bowen D; Hellström Lindberg E; CAZZOLA, MARIO; Wainscoat JS
The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.
Rivista: PLOS ONE - Volume: 3 - Pagine: e1970-Anno: 2008
(1 Contributo su Rivista)
DELLA PORTA, MATTEO GIOVANNI; MALCOVATI, LUCA; Rigolin GM; Rosti V; Bonetti E; Travaglino E; Boveri E; Gallì A; Boggi S; Ciccone M; Pramparo T; Mazzini G; INVERNIZZI, ROSANGELA; LAZZARINO, MARIO; CAZZOLA, MARIO
Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes.
Rivista: LEUKEMIA - Volume: 22 - Pagine: 530-537 - Num. pagine: 8 - Anno: 2008
(1 Contributo su Rivista)
Jädersten M; MALCOVATI, LUCA; Dybedal I; DELLA PORTA, MATTEO GIOVANNI; INVERNIZZI, ROSANGELA; Montgomery SM; Pascutto C; Porwit A; CAZZOLA, MARIO; Hellström Lindberg E.
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
Rivista: JOURNAL OF CLINICAL ONCOLOGY - Volume: 26 - Pagine: 3607-3613 - Num. pagine: 7 - Anno: 2008
(1 Contributo su Rivista)
Passamonti F; RUMI, ELISA; ARCAINI, LUCA; Boveri E; ELENA, CHIARA; Pietra C; Boggi S; Astori C; BERNASCONI, PAOLO; Varettoni M; Brusamolino E; Pascutto C; Lazzarino M.
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
Rivista: HAEMATOLOGICA - Volume: 93 - Pagine: 1645-1651 - Num. pagine: 7 - Anno: 2008
(1 Contributo su Rivista)
PASSAMONTI, FRANCESCO; RUMI, ELISA; Caramella M; ELENA, CHIARA; ARCAINI, LUCA; Boveri E; Del Curto C; Pietra D; Vanelli L; BERNASCONI, PAOLO; Pascutto C; CAZZOLA, MARIO; Morra E; LAZZARINO, MARIO
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
Rivista: BLOOD - Volume: 111 - Pagine: 3383-3387 - Num. pagine: 5 - Anno: 2008
(1 Contributo su Rivista)
Pellagatti A; Hellström Lindberg E; Giagounidis A; Perry J; MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Jädersten M; Killick S; Fidler C; CAZZOLA, MARIO; Wainscoat JS; Boultwood J.
Haploinsufficiency of RPS14 in 5q− syndrome is associated with deregulation of ribosomal- and translation-related genes
Rivista: BRITISH JOURNAL OF HAEMATOLOGY - Volume: 142 - Pagine: 57-64 - Num. pagine: 8 - Anno: 2008
(1 Contributo su Rivista)
Wang L; Fidler C; Nadig N; Giagounidis A; DELLA PORTA, MATTEO GIOVANNI; MALCOVATI, LUCA; Killick S; Gattermann N; Aul C; Boultwood J; Wainscoat JS
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
Rivista: HAEMATOLOGICA - Volume: 93 - Pagine: 994-1000 - Num. pagine: 7 - Anno: 2008
(1 Contributo su Rivista)
Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Jädersten M; Killick S; Fidler C; CAZZOLA, MARIO; Hellström Lindberg E; Wainscoat J.S.
Gene expression profiling of CD34+ cells in patients with the 5q- syndrome
Rivista: BRITISH JOURNAL OF HAEMATOLOGY - Volume: 139 - Pagine: 578-589 - Num. pagine: 12 - Anno: 2007
(1 Contributo su Rivista)
MALCOVATI, LUCA; Germing U; Kuendgen A; DELLA PORTA, MATTEO GIOVANNI; Pascutto C; INVERNIZZI, ROSANGELA; Giagounidis A; Hildebrandt B; BERNASCONI, PAOLO; Knipp S; Strupp C; LAZZARINO, MARIO; Aul C; CAZZOLA, MARIO
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Rivista: JOURNAL OF CLINICAL ONCOLOGY - Volume: 25 - Pagine: 3503-3510 - Num. pagine: 8 - Anno: 2007
(1 Contributo su Rivista)
Passamonti F; Randi ML; RUMI, ELISA; Pungolino E; ELENA, CHIARA; Pietra D; Scapin M; ARCAINI, LUCA; Tezza F; MORATTI, REMIGIO; Pascutto C; Fabris F; Morra E; CAZZOLA, MARIO; Lazzarino M.
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
Rivista: BLOOD - Volume: 110 - Pagine: 485-489 - Num. pagine: 5 - Anno: 2007
(1 Contributo su Rivista)
RUMI, ELISA; PASSAMONTI, FRANCESCO; DELLA PORTA, MATTEO GIOVANNI; ELENA, CHIARA; ARCAINI, LUCA; Vanelli, L; DEL CURTO, CECILIA; PIETRA, DANIELA; BOVERI, EMANUELA; PASCUTTO, CRISTIANA; CAZZOLA, MARIO; LAZZARINO, MARIO
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation
Rivista: JOURNAL OF CLINICAL ONCOLOGY - Volume: 25 - Pagine: 5630-5635 - Num. pagine: 6 - Anno: 2007
(1 Contributo su Rivista)
DELLA PORTA, MATTEO GIOVANNI; MALCOVATI, LUCA; INVERNIZZI, ROSANGELA; Travaglino E; Pascutto C; Maffioli M; Gallì A; Boggi S; Pietra D; Vanelli L; Marseglia C; Levi S; Arosio P; LAZZARINO, MARIO; CAZZOLA, MARIO
Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome.
Rivista: LEUKEMIA - Volume: 20 - Pagine: 549-555 - Num. pagine: 7 - Anno: 2006
(1 Contributo su Rivista)
Pellagatti A; CAZZOLA, MARIO; Giagounidis AA; MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Killick S; Campbell LJ; Wang L; Langford CF; Fidler C; Oscier D; Aul C; Wainscoat JS; Boultwood J.
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype
Rivista: BLOOD - Volume: 108 - Pagine: 337-345 - Num. pagine: 9 - Anno: 2006
(1 Contributo su Rivista)
RUMI, ELISA; Passamonti F; Pietra D; DELLA PORTA, MATTEO GIOVANNI; ARCAINI, LUCA; Boggi S; ELENA, CHIARA; Boveri E; Pascutto C; Lazzarino M; CAZZOLA, MARIO
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders
Rivista: CANCER - Volume: 107 - Pagine: 2206-22011 - Num. pagine: 19806 - Anno: 2006
(1 Contributo su Rivista)
CAZZOLA, MARIO; MALCOVATI, LUCA
Myelodysplastic syndromes--coping with ineffective hematopoiesis.
Rivista: NEW ENGLAND JOURNAL OF MEDICINE - Volume: 352 - Pagine: 536-538 - Num. pagine: 3 - Anno: 2005
(1 Contributo su Rivista)
Kralovics R; Teo SS; Buser AS; Brutsche M; Tiedt R; Tichelli A; PASSAMONTI, FRANCESCO; Pietra D; CAZZOLA, MARIO; Skoda RC
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
Rivista: BLOOD - Volume: 106 - Pagine: 3374-3376 - Num. pagine: 3 - Anno: 2005
(1 Contributo su Rivista)
MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Lunghi M; Pascutto C; Vanelli L; Travaglino E; Maffioli M; BERNASCONI, PAOLO; LAZZARINO, MARIO; INVERNIZZI, ROSANGELA; CAZZOLA, MARIO
Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome
Rivista: LEUKEMIA - Volume: 19 - Pagine: 776-783 - Num. pagine: 7 - Anno: 2005
(1 Contributo su Rivista)
MALCOVATI, LUCA; DELLA PORTA, MATTEO GIOVANNI; Pascutto C; INVERNIZZI, ROSANGELA; Boni M; Travaglino E; PASSAMONTI, FRANCESCO; ARCAINI, LUCA; Maffioli M; BERNASCONI, PAOLO; LAZZARINO, MARIO; CAZZOLA, MARIO
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making
Rivista: JOURNAL OF CLINICAL ONCOLOGY - Volume: 23 - Pagine: 7594-7603 - Num. pagine: 9 - Anno: 2005
(1 Contributo su Rivista)
PASSAMONTI, FRANCESCO; RUMI, ELISA; Pungolino E; Malabarba L; Bertazzoni P; Valentini M; Orlandi E; ARCAINI, LUCA; Brusamolino E; Pascutto C; CAZZOLA, MARIO; Morra E; LAZZARINO, MARIO
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
Rivista: THE AMERICAN JOURNAL OF MEDICINE - Volume: 117 - Pagine: 755-761 - Num. pagine: 7 - Anno: 2004
(1 Contributo su Rivista)

 

Punti di forza comparativi dell'unità di ricerca in un orizzonte di 3-5 anni


The strength of our search unit is primarily a well-characterized population of patients with myeloproliferative neoplasms, which represents an invaluable basis for both translational research and clinical trials: we deeply wish to thank all patients who agreed to participate in our studies.

Two institutions have been of fundamental importance for the development of our research activity:

1) Associazione Italiana per la Ricerca sul Cancro (AIRC, http://www.airc.it/), which has regularly funded Mario Cazzola since 1986;

2) Fondazione Cariplo (http://www.fondazionecariplo.it/portal/), which has co-funded our genomic studies on myeloproliferative neoplasms.

Our major strength in the next 5 years will definitely derive from the AIRC decision to fund our studies on myeloproliferative neoplasms within the Special Program Molecular Clinical Oncology 5 per mille. To this purpose we have created the ad hoc AGIMM group: please visit its website (http://www.progettoagimm.it/index_en.shtml) for details.

Finally, our studies could not have been performed without our marvelous international collaborators.